Ovid Therapeutics Inc. (OVID)

NCM – Real vaqt narxi. Valyuta: USD

2.87

+0.08 (2.87%)

Yopilishda: May 12, 2026, 4:00 PM EDT

2.90

+0.03 (1.05%)

Bozor oldidan: May 13, 2026, 7:18 AM EDT

Kompaniya haqida

Ovid Therapeutics Inc., biotexnologiya kompaniyasi, AQShda epilepsiya va tirishish bilan bog'liq nevrologik kasalliklar, shu jumladan miya kasalliklari uchun kichik molekulali dori vositalarini ishlab chiqish bilan shug'ullanadi. Kompaniya OV329, GABAA-AT inhibitorni ishlab chiqmoqda, u kattalar va chaqaloqlardagi dori-darmonga chidamli epilepsiyani davolash uchun 1-bosqich klinik sinovlarida; va OV4071, Parkinson kasalligi, Lewy tana demansiyasi va o'tkir shizofreniya bilan bog'liq psixozni davolash uchun 1-bosqich klinik sinovlarida bo'lgan birinchi inson og'zaki kaliy-xlorid kotransporter 2 to'g'ridan-to'g'ri faollashtiruvchisi. Kompaniya AstraZeneca AB, H. Lundbeck A/S, Shimoli-g'arbiy universitet va Graviton, shuningdek Marinus Pharmaceuticals, Inc. bilan litsenziya va hamkorlik shartnomalariga ega. Kompaniya 2014 yilda tashkil etilgan va shtab-kvartirasi Nyu-York, Nyu-Yorkda joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.	Co-Founder & Executive Chairman
Dr. Julia Tsai Ph.D.	Senior Vice President of Clinical Development
Dr. Manal Morsy M.B.A., M.D., PH.D.	Chief Regulatory Officer
Dr. Petra Kaufmann M.D., M.S.	Chief Medical Officer
Dr. Toshiya Nishi D.V.M.	Head of Epilepsy Research
Dr. Zhong Zhong Ph.D.